GSK boosts 2031 revenue target to over £40bn following robust Q4 results
Pharmaceutical titan GSK has raised its 2031 sales forecast to over £40bn, an increase from the previously projected £38bn, following a stronger-than-anticipated performance in the fourth quarter.
The London-listed pharmaceutical behemoth disclosed core earnings per share of 23.2p for the quarter, which, despite being a roughly 20% decline year-on-year, exceeded the analysts' expectations of 19p, as reported by City AM.
For the entire year of 2024, GSK reported core earnings per share of 159.3p, marking a 10% rise at constant exchange rates. Turnover climbed by seven percent at constant exchange rates to £31.4bn, or by eight percent when excluding sales
Recommend
Exeter wholesale broadband company agrees merger
2025-04-15 11:56:11
2025-04-15 11:56:11
Sheffield battery firm seals $7m funding to roll out clean energy tech in Africa
2025-04-15 11:56:11
2025-04-15 11:56:11
Newcastle canning company CRL Foods gets £1m Northern Powerhouse investment
2025-04-15 11:56:11
2025-04-15 11:56:11
Anglo American presses ahead with demerger of platinum business
2025-04-15 11:56:11
2025-04-15 11:56:11
SMEs could win more public sector contracts under new AI-powered procurement pilot in Greater Manchester
2025-04-15 11:56:11
2025-04-15 11:56:11
Healthtech start-up bags Europe's largest pre-seed funding round for female founders
2025-04-15 11:56:11
2025-04-15 11:56:11
UK Government achieves NHS appointment target early, yet challenges remain
2025-04-15 11:56:11
2025-04-15 11:56:11
10 questions for Sarah Thackray of Beaconhouse Events
2025-04-15 11:56:11
2025-04-15 11:56:11
Wiltshire pet insurance firm snaps up dog health app
2025-04-15 11:56:11
2025-04-15 11:56:11
Moonpig founder and former Dragons' Den star opens new Wiltshire business school
2025-04-15 11:56:11
2025-04-15 11:56:11
